Stockscreener 앱 받기
22.75
1.25%
0.3492
전일 마감가:
$22.40
열려 있는:
$22.46
하루 거래량:
282.18K
Relative Volume:
0.17
시가총액:
$2.48B
수익:
-
순이익/손실:
$-183.79M
주가수익비율:
-10.99
EPS:
-2.0691
순현금흐름:
$-131.84M
1주 성능:
+10.69%
1개월 성능:
+11.01%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$22.46
$22.90
1주일 범위
$20.42
$22.90
52주 변동 폭
$14.62
$26.25
Definium Therapeutics Inc Stock (DFTX) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
22.73 | 2.44B | 0 | -183.79M | -131.84M | -2.0691 |
VRTX
Vertex Pharmaceuticals Inc
|
428.25 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.03 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.18 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.00 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Stifel | Buy |
| 2026-04-10 | 개시 | Piper Sandler | Overweight |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Definium Therapeutics (DFTX) Expands DT120 ODT Into PTSD Can Its Psychedelic Strategy Scale Across Psychiatry? - simplywall.st
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated May 2026 - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation As DT120 ODT Nears Key Phase 2 And Phase 3 Readouts - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 213% One Year Surge? - Sahm
Definium Therapeutics to hold live Q1 financial webcast on May 7 - Traders Union
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 - The Joplin Globe
A Look At Definium Therapeutics (DFTX) Valuation After Recent Share Price Volatility - Sahm
Definium Therapeutics (DFTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update - MarketBeat
Can Definium Therapeutics' (DFTX) LSD Platform Strategy Reframe Its Risk Profile Across Brain Health Disorders? - simplywall.st
Definium Therapeutics (STU:MMQ0) Shiller PE Ratio : (As of May. 02, 2026) - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 6.7%Here's What Happened - MarketBeat
Definium Therapeutics (DFTX) details 2026 virtual meeting and equity plan vote - Stock Titan
These 3 Psychedelic Stocks Activated After Trump’s Executive Order - Investing.com
These 3 Psychedelic Stocks Activated After Trump's Executive Order - MarketBeat
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst - MSN
Q1 Earnings Estimate for DFTX Issued By HC Wainwright - MarketBeat
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Definium Therapeutics, Inc. (DFTX) Analyst/Investor DaySlideshow (NASDAQ:DFTX) 2026-04-24 - Seeking Alpha
Definium Therapeutics (DFTX) stock gains after hours: Here's what's driving the move - MSN
Definium Therapeutics : Investor & Analyst Day April 2026 - marketscreener.com
Definium Therapeutics Investor Day: DT120 Phase III Readouts Set for Late Q2–Q3, PTSD Plan for 2027 - Yahoo Finance
Stifel reiterates Definium Therapeutics stock rating on trial confidence - Investing.com UK
Stifel reiterates Definium Therapeutics stock rating on trial confidence By Investing.com - Investing.com Australia
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $28 to $70 - Moomoo
H.C. Wainwright reiterates Definium stock rating at buy on phase 3 progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Definium stock rating at buy on phase 3 progress - Investing.com
Definium Therapeutics (DFTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 311% One Year Surge? - Sahm
Oppenheimer Adjusts Definium Therapeutics PT to $40 From $25, Maintains Outperform Rating - marketscreener.com
Piper Sandler reiterates Definium stock rating on development plan By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $28 to $49 - Moomoo
The Bull Case For Definium Therapeutics (DFTX) Could Change Following US Psychedelic Policy Momentum - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Definium expects three trial readouts for depression, anxiety drug By Investing.com - Investing.com India
DFTX (Definium Therapeutics Inc. Common Shares) posts narrow Q4 2025 EPS miss, trades slightly higher in today’s market session.Earnings Beat - Cổng thông tin điện tử tỉnh Lào Cai
Definium Therapeutics (DFTX) Advances Clinical Programs and Comm - GuruFocus
Definium expects three trial readouts for depression, anxiety drug - Investing.com
Definium Highlights DT120 Phase 3 Progress in Depression, Anxiety - TipRanks
Definium Therapeutics highlights advancement of DT120 ODT - TipRanks
Definium Therapeutics accelerates psychedelic treatment momentum with New York investor summit - Traders Union
Definium Therapeutics Highlights Clinical Advancements And Commercial Strategy For DT120 ODT - marketscreener.com
Transcript : Definium Therapeutics, Inc.Analyst/Investor Day - marketscreener.com
DFTX: DT120 targets major psychiatric disorders with pivotal data and commercial launch readiness in 2024 - TradingView
DFTX: DT-120 aims to transform psychiatric care with rapid, durable relief and broad market potential - TradingView
DFTX Maintained by Leerink Partners -- Price Target Raised to $3 - GuruFocus
Leerink Partners Issues Positive Forecast for Definium Therapeutics (NASDAQ:DFTX) Stock Price - MarketBeat
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day - Business Wire
DFTX News Today | Why did Definium Therapeutics stock go up today? - MarketBeat
Definium Therapeutics Inc (DFTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Definium Therapeutics Inc 주식 (DFTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Mar 25 '26 |
Sale |
18.47 |
10,702 |
197,666 |
271,079 |
| Barrow Robert | Chief Executive Officer |
Mar 25 '26 |
Sale |
18.47 |
24,431 |
451,241 |
752,454 |
0.78%
3.01%
자본화:
|
볼륨(24시간):